A beginner's guide to FDA-approved peptides

The peptide approval gap

Most peptides discussed online are not FDA-approved. Of the hundreds of sequences biohackers and longevity enthusiasts talk about, only a fraction have completed the clinical trial process. That gap determines what a physician can prescribe, what insurance might cover, and what legal protection exists if something goes wrong.

Most peptides discussed in online communities are not FDA-approved. Out of the hundreds of peptide sequences that biohackers, bodybuilders, and longevity enthusiasts talk about, only a fraction have completed the rigorous clinical trial process required for FDA approval. The disconnect between what is popular and what is approved creates real confusion.

Peptide drugs are a large and growing class: more than 80 peptide drugs have reached the market worldwide, with dozens more in clinical development [1]. But the peptides dominating Reddit threads and Telegram groups, BPC-157, TB-500, MOTS-c, and KPV, are not among them. They sit in a regulatory gray area: widely used, but lacking the kind of large, well-controlled human trials that drug approval requires [18], the kind semaglutide and tirzepatide went through.

The approved peptide drugs this guide covers, with what each one is approved for:

Understanding which peptides are actually approved, which are in the pipeline, and which are strictly research compounds is not just academic. It determines what a physician can legally prescribe, what insurance might cover, and what legal protections exist if something goes wrong.

FDA-approved peptide therapeutics

These peptide drugs completed the FDA approval process: clinical trial evidence reviewed by the agency, a defined safety profile, and at least one approved indication. The list spans blockbuster metabolic drugs like semaglutide and tirzepatide through rare-disease treatments for Rett syndrome, Barth syndrome, hypoparathyroidism, and erythropoietic protoporphyria.

The following peptide drugs have completed the full FDA approval process. This is a selection of the ones people ask about most, not the full list: more than 80 peptide drugs have reached the market worldwide [1]. Each one has clinical trial evidence the FDA reviewed, a defined safety profile, and at least one approved indication. They represent the gold standard of what peptide medicine looks like when it goes through the system.

Semaglutide

For weight management, Novo Nordisk launched the Wegovy injection in 2021 [21], and on 22 December 2025 the FDA approved the Wegovy pill, a once-daily 25 mg tablet that Novo Nordisk calls the first oral GLP-1 medicine for obesity in the US [21]. For type 2 diabetes, semaglutide in pill form was first approved in 2019 as Rybelsus; in May 2026 Novo Nordisk renamed it in the US as the Ozempic pill, in an updated formulation, so Ozempic is now available both as an injection and as a pill [19]. The STEP 1 trial showed 14.9% mean weight loss at 68 weeks [2]. The oral 25 mg version, taken once daily, achieved 13.6% mean weight loss at 64 weeks in the OASIS 4 trial, versus 2.2% on placebo [3].

Tirzepatide

A dual GIP/GLP-1 receptor agonist. It was first approved in May 2022 as Mounjaro, to improve blood sugar control in diabetes [30]. In November 2023 the FDA approved it as Zepbound for chronic weight management in adults with obesity, or overweight with at least one weight-related condition [31]. On 20 December 2024 the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, calling it the first drug treatment option for certain patients with the condition [4]. The SURMOUNT-5 head-to-head trial showed 20.2% weight loss versus 13.7% for semaglutide at 72 weeks [5].

Afamelanotide (Scenesse)

A subcutaneous implant. The FDA approved it in October 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare condition that makes sunlight painful [28]. This is what the peptide community knows as melanotan I. The implant is made of a bioabsorbable PLGA polymer. Critical distinction: it is not approved for tanning.

Setmelanotide (Imcivree)

An MC4R agonist given as a daily subcutaneous injection. The FDA first approved it in November 2020 to treat obesity and hunger caused by pro-opiomelanocortin (POMC) deficiency, a rare genetic disorder [29]. Its label has since grown to other rare genetic causes of obesity, including Bardet-Biedl syndrome, and to younger children. On 19 March 2026 the FDA expanded it to acquired hypothalamic obesity (weight gain caused by damage to the hypothalamus, the brain region that regulates appetite) in adults and children aged 4 and older [24].

Trofinetide (Daybue)

An oral solution. The FDA approved it in March 2023 to treat Rett syndrome [32]. The first and only drug for this condition. It is a synthetic analog of the N-terminal tripeptide of IGF-1.

Palopegteriparatide (Yorvipath)

A subcutaneous injection. The FDA approved it in August 2024 to treat hypoparathyroidism (too little parathyroid hormone) [33]. It is a prodrug of PTH(1-34).

Elamipretide (Forzinity)

A subcutaneous injection. The FDA granted it accelerated approval in September 2025 to improve muscle strength in patients with Barth syndrome weighing at least 30 kg [34]. The first mitochondria-targeted therapeutic. It binds cardiolipin on the inner mitochondrial membrane.

Bremelanotide (Vyleesi)

The FDA approved it in June 2019 as a subcutaneous injection [27]. It treats hypoactive sexual desire disorder in premenopausal women.

Tesamorelin (Egrifta)

The FDA approved it in November 2010 as a subcutaneous injection [26]. It treats HIV-associated lipodystrophy, an abnormal build-up of belly fat in some people with HIV, and is a growth hormone-releasing hormone analog.

Not a peptide: orforglipron (Foundayo)

One 2026 approval belongs next to this list because it is not on it. On 1 April 2026 the FDA approved Foundayo (orforglipron), an Eli Lilly pill taken once a day, for adults with obesity, or overweight with weight-related medical problems [11]. Lilly describes it as a small molecule (non-peptide) GLP-1 receptor agonist: it switches on the same receptor as semaglutide without being a peptide at all. In the ATTAIN-1 trial, people on the highest dose who stayed on treatment lost an average of 12.4% of their body weight, versus 0.9% on placebo, and 11.1% versus 2.1% when everyone was counted regardless of whether they finished the trial [11]. The Wegovy pill was already a GLP-1 pill for weight loss, but it is semaglutide, a peptide; Foundayo is the first one that is not.

How peptides get into your body

The administration route decides bioavailability, convenience, and who can realistically use a drug. Most approved peptide drugs are injected under the skin (subcutaneously) because peptides are large, fragile molecules that the gut destroys. Oral, implant, and nasal routes each solve that problem differently, and each pays a different price.

The administration route determines bioavailability, convenience, and which patients can actually use a drug. Peptides are large, fragile molecules, and getting them into the bloodstream intact is one of the central challenges of peptide pharmacology.

Subcutaneous injection

The default route for peptide drugs, because peptides are large molecules that get destroyed in the gut. Absorption is reliable, bioavailability is high, and auto-injector pens have made the process almost trivial for patients. Semaglutide, tirzepatide, setmelanotide, bremelanotide, tesamorelin, palopegteriparatide, and elamipretide all use this route.

Oral delivery

Oral delivery is the hardest route for a large peptide. Novo Nordisk made it work for semaglutide with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) technology. SNAC creates a local pH buffer in the stomach that protects semaglutide from enzymatic degradation and enhances absorption across the gastric epithelium [6]. Even so, only a small fraction is absorbed: the label for the Rybelsus and Ozempic tablets puts semaglutide's absolute bioavailability (the share of a dose that reaches the bloodstream) at roughly 0.4% to 2%, and tells patients to take the tablet on an empty stomach and wait at least 30 minutes before eating or drinking [20]. Trofinetide (Daybue) is also administered orally, as a solution.

Subcutaneous implants

Implants provide weeks to months of sustained release. Afamelanotide's PLGA implant is one example; goserelin (Zoladex) for prostate cancer and histrelin (Supprelin LA) use the same concept. The trade-off is a minor procedure for insertion.

Nasal spray

The nasal route bypasses first-pass liver metabolism and delivers peptides directly to the bloodstream through the nasal mucosa. Desmopressin for diabetes insipidus and calcitonin for osteoporosis use this route. Selank and Semax are administered nasally in Russia, where intranasal Semax has been studied in healthy volunteers [7], though neither has FDA approval.

Emerging delivery technologies

Lipid nanoparticles and transdermal microneedle patches are in active development for peptides. The oral problem has also been sidestepped from the other direction: orforglipron (Foundayo), approved in April 2026, avoids the peptide absorption problem by not being a peptide, and Lilly says it can be taken at any time of day without food or water restrictions [11].

The pipeline: what is coming next

Three candidates are generating the most clinical interest: retatrutide, a triple agonist whose top dose averaged 28.3% weight loss in its pivotal trial on the estimate that assumes everyone stayed on treatment, CagriSema, an amylin and GLP-1 combination with an FDA decision expected in late 2026, and survodutide, a dual agonist aimed at liver disease and weight.

Three candidates are generating the most clinical excitement right now. Each one addresses a different unmet need, and all three could reshape their respective therapeutic areas.

Retatrutide

Eli Lilly's triple agonist (GIP, GLP-1, and glucagon receptors). Phase 2 data showed up to 24.2% weight loss at 48 weeks [8]. The pivotal phase 3 TRIUMPH-1 trial reported an average 28.3% weight loss at 80 weeks on the 12 mg dose in a study of 2,339 participants [12]. That figure is Lilly's efficacy estimand (an estimate of the result had everyone stayed on treatment); counting everyone regardless of adherence, the 12 mg figure was 25.0% [12]. TRIUMPH-2 and TRIUMPH-3 have since read out too, and Lilly plans to submit retatrutide to the FDA in the first quarter of 2027 [13], so no approval decision can come before then. For a full breakdown of what the trial data showed and what questions remain, see our retatrutide TRIUMPH-1 results explainer.

CagriSema

Novo Nordisk's fixed-dose combination of cagrilintide (an amylin analog) and semaglutide. Novo Nordisk filed a New Drug Application with the FDA in December 2025, and in September 2026 said a decision is expected in the fourth quarter of 2026 [14]. The REDEFINE 1 trial showed 20.4% mean weight loss at 68 weeks versus 3.0% with placebo [9]. Our CagriSema REDEFINE-1 results explainer covers the trial design and what the data means for the next-generation GLP-1 landscape.

Survodutide

Boehringer Ingelheim's dual glucagon/GLP-1 agonist targeting MASH (metabolic dysfunction-associated steatohepatitis, an inflammatory form of fatty liver disease) with liver fibrosis. It received FDA breakthrough therapy designation in September 2024 [16]. The phase 2 trial showed MASH improvement without worsening of fibrosis in 62% of patients on the 4.8 mg dose, versus 14% on placebo [10]. For weight, the phase 3 SYNCHRONIZE-1 trial reported a 13.0% mean weight loss at 76 weeks on the 6.0 mg dose versus 5.4% on placebo, counting everyone regardless of adherence [15].

The compounding reclassification

In April 2026 the FDA moved 12 peptides, BPC-157 among them, off its category 2 compounding list after their nominations were withdrawn. This is the most misread event in peptide regulation: leaving category 2 is not FDA approval, and it is not the same as being added to the 503A authorized bulk substances list.

In late 2023 the FDA placed a group of widely used peptides into category 2, its list of bulk drug substances that may present significant safety risks [25]. For a category 2 substance, the FDA says it would consider taking action against a compounder who uses it [35]. The list included BPC-157, TB-500, GHK-Cu, KPV, MOTS-c, Semax, Epitalon, and others.

In April 2026 the FDA updated its category 2 page, and these 12 peptides now sit in its table of nominations withdrawn by the nominators [17]: BPC-157, cathelicidin LL-37, dihexa acetate, emideltide (DSIP), Epitalon, GHK-Cu (injectable routes only), KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500. An archived copy of the same page from 4 April 2026 still lists each of these 12 inside category 2 [25]. Five other substances in the withdrawn table, AOD-9604, CJC-1295, ipamorelin acetate, Selank, and thymosin alpha-1, were already listed outside the 503A category 2 table before April [25]. Ipamorelin acetate still sits in category 2 for 503B outsourcing facilities [17].

What that move means: the 12 peptides are no longer in category 2, although the FDA still publishes its safety concerns for each of them on the same page [17].

What it does not mean: it is not FDA approval, and on its own it does not authorize compounding. Leaving category 2 does not place a substance on the 503A authorized list, which requires a separate advisory review and an FDA decision. The FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to review seven of them for that list: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon [23]. FDA scientists advised the panel to vote no, and by narrow margins it voted in favor of six: BPC-157, MOTS-c, KPV, TB-500, Epitalon, and Semax, with emideltide the only one voted down [18]. That vote is a recommendation, not a decision. The FDA is not required to follow it, and adding the peptides to the list would go through a formal rulemaking process that could stretch into 2027 or 2028 [18]. Our July 2026 FDA panel vote explainer covers the meeting in detail.

What changed on October 30, 2026: HHS published a draft interim policy saying it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with certain peptides while the 503A list is developed through rulemaking [36]. It covers six of them, BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c, each limited to specific routes, and its conditions include an FDA-registered manufacturer, a certificate of analysis, a patient-specific prescription, a single active ingredient and adverse-event reporting to MedWatch [37]. It is enforcement discretion, not approval: none of the six is on the 503A list or FDA-approved, and the policy does not cover 503B outsourcing facilities, research chemicals or dietary supplements [37]. Emideltide, GHK-Cu, LL-37, dihexa, Melanotan II and PEG-MGF are not covered.

None of these peptides have completed phase 3 clinical trials for their commonly promoted uses, and none are FDA-approved for any condition. The clinical evidence for most of them remains limited to cell studies, animal models, and small uncontrolled human studies. For a detailed account of the reclassification and its practical implications, see the FDA category-2 reclassification explainer. For background on the chemistry differences between approved drugs and research peptides, the natural vs synthetic peptides guide covers the four origin categories in plain English.

Six misconceptions that trip people up

Six claims come up constantly and all six are wrong: that "research use only" implies human safety, that personal use is legally protected, that off-label prescribing covers unapproved peptides, that leaving category 2 equals approval, that all peptides share a risk profile, and that compounded equals equivalent.

1. "Research use only" means it is safe for humans. False. RUO is a legal disclaimer for laboratory reagents, not a quality standard for human use. It explicitly means the product has not been validated for diagnostic or therapeutic application.
2. Buying unapproved peptides for personal use is legally protected. False. Buying peptides online outside a regulated pharmacy dispensing pathway has no legal protection. The FDA considers unapproved peptides sold for human use to be misbranded and adulterated drugs.
3. Off-label prescribing covers research peptides. False. Off-label use applies only to drugs already FDA-approved for at least one condition. BPC-157 has zero approvals, so off-label does not apply.
4. Removal from category 2 equals FDA approval. False, and this is the single most common error since April 2026. Removal lifts a prohibition-style designation. It says nothing about efficacy, it does not place a substance on the 503A authorized list, and it is a regulatory pathway decision rather than a clinical endorsement.
5. All peptides carry the same risk profile. False. Semaglutide has been through large randomized trials such as STEP 1 [2]. BPC-157's human safety data comes from a handful of small studies. Equating their risk profiles is a category error.
6. Compounded peptides are identical to FDA-approved versions. False. Compounded drugs are not FDA-approved, which means the FDA does not verify their safety, effectiveness, or quality before they are marketed [22]. Quality depends entirely on the compounding pharmacy's standards and oversight.

If you are still working out whether any of this applies to you, the beginner's decision guide walks through the questions worth answering before the regulatory status of a specific compound matters at all. The explorer below lets you filter the peptides it covers by approval status, route, and category.